Automated Geriatric Co-Management Program in Older Patients With Solid Mass or Nodule Suspicious for Cancer

Sponsor
Memorial Sloan Kettering Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT03885908
Collaborator
(none)
200
1
2
47.4
4.2

Study Details

Study Description

Brief Summary

The purpose of this study is to find out if it is possible to use the automated geriatric co-management program to manage the participants care before, during and after surgery.

Condition or Disease Intervention/Treatment Phase
  • Other: in-person geriatric co-management
  • Other: automated geriatric co-management
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The proposed study is a randomized controlled trial study.The proposed study is a randomized controlled trial study.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Feasibility and Effectiveness of Automated Geriatric Co-Management Program on Improving the Perioperative Care of Older Patients With Solid Mass or Nodule Suspicious for Cancer
Actual Study Start Date :
Mar 19, 2019
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: In-person geriatric co-management group

"In-person" geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety.

Other: in-person geriatric co-management
The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. "In-person" geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety.

Experimental: Automated geriatric co-management program group

Other: automated geriatric co-management
Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.

Outcome Measures

Primary Outcome Measures

  1. feasibility of automated geriatric co-management program [2 years]

    percentage of recommendations that were followed by the surgery team

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Solid mass or nodule suspicious for cancer

  • Aged 65 or older

  • Being considered for surgical resection of the solid mass or nodule, with anticipated hospital length of stay of at least two days,

  • Completed the eRFA per routine care

Exclusion Criteria:
  • Unable to read or comprehend English

  • Not having a completed electronic Rapid Fitness Assessment within 2 months of surgery**Note) To avoid excluding patients based this item, patients have to complete another eRFA within two months of surgery.

  • Being discharged in one day or earlier from the hospital.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Memorial Sloan Kettering Cancer Center New York New York United States 10065

Sponsors and Collaborators

  • Memorial Sloan Kettering Cancer Center

Investigators

  • Principal Investigator: Armin Shahrokni, MD, MPH, Memorial Sloan Kettering Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT03885908
Other Study ID Numbers:
  • 19-066
First Posted:
Mar 22, 2019
Last Update Posted:
Dec 16, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Memorial Sloan Kettering Cancer Center

Study Results

No Results Posted as of Dec 16, 2021